Universal Beteiligungs und Servicegesellschaft mbH Has $63.12 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Universal Beteiligungs und Servicegesellschaft mbH increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 60.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 150,298 shares of the company's stock after purchasing an additional 56,408 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.19% of IDEXX Laboratories worth $63,118,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in IDXX. Choreo LLC increased its position in IDEXX Laboratories by 4.3% in the 1st quarter. Choreo LLC now owns 1,544 shares of the company's stock valued at $648,000 after acquiring an additional 64 shares during the period. Crystal Rock Capital Management raised its stake in IDEXX Laboratories by 24.2% during the 1st quarter. Crystal Rock Capital Management now owns 11,185 shares of the company's stock valued at $4,697,000 after acquiring an additional 2,180 shares in the last quarter. PFG Advisors raised its stake in IDEXX Laboratories by 39.0% during the 1st quarter. PFG Advisors now owns 10,375 shares of the company's stock valued at $4,357,000 after acquiring an additional 2,910 shares in the last quarter. HighPoint Advisor Group LLC raised its stake in IDEXX Laboratories by 64.9% during the 1st quarter. HighPoint Advisor Group LLC now owns 915 shares of the company's stock valued at $400,000 after acquiring an additional 360 shares in the last quarter. Finally, Crestwood Advisors Group LLC bought a new stake in IDEXX Laboratories during the 1st quarter valued at $348,000. Institutional investors own 87.84% of the company's stock.

Analysts Set New Price Targets

Several brokerages have weighed in on IDXX. Morgan Stanley lifted their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research note on Monday, May 5th. Jefferies Financial Group began coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Wall Street Zen raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Finally, Stifel Nicolaus lifted their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the company a "hold" rating in a research note on Wednesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $557.88.

IDEXX Laboratories Price Performance

Shares of IDXX traded up $15.22 during midday trading on Friday, reaching $565.19. The stock had a trading volume of 1,071,473 shares, compared to its average volume of 425,413. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $568.47. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.16 and a quick ratio of 0.81. The firm's 50 day moving average price is $526.59 and its 200-day moving average price is $467.17. The company has a market capitalization of $45.45 billion, a P/E ratio of 52.24, a P/E/G ratio of 4.11 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The company's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company posted $2.71 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other news, Director M Anne Szostak sold 1,260 shares of the business's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director directly owned 1,801 shares of the company's stock, valued at $922,724.34. The trade was a 41.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.